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During the last 20 years, a multitude of cytotoxic drugshave been tested in malignant pleural mesothelioma
(MPM), both as single agents and within combination regi-
mens. Of the single-agent drugs, the most commonly effec-
tive drugs are cisplatin, methotrexate, and trimetrexate. The
antimetabolites, particularly anti-folates, have the highest
response rates, whereas platinum compounds and anthracy-
clines have a slightly lower response rate.1 From these earlier
small phase II trials enrolling a limited number of poorly
staged patients, it became clear that there was a limited
advantage to using combination chemotherapy compared
with single agents for MPM. More recently, however, the
combination of an antimetabolite and a platinum derivative
has emerged as the standard of treatment for patients with
MPM,2 although, once again, the use of doublets of cytotoxic
drugs was mainly supported by the results of phase II studies.
Among the most commonly used doublets, alimta and cis-
platinum,2 cisplatin (or carboplatin) and gemcitabine,3,4 or
raltitrexed and oxaliplatin5,6 have emerged as the most prom-
ising in a first-line setting.
PROGNOSTIC FACTORS AND RESPONSE
CRITERIA
Parallel with these studies, novel methods for the mea-
surement of response in MPM to chemotherapy have been
developed, and poor-risk prognostic categories have been
further stratified for therapy of the disease. Applying Re-
sponse Evaluation Criteria in Solid Tumors (RECIST) crite-
ria7 for defining radiologic response of solid tumors to MPM
proved difficult and required modification. The new modified
RECIST criteria for the assessment of response in MPM8
measure the tumor thickness perpendicular to the chest wall
or mediastinum in up to three involved areas of pleural rind.
Each rind can be measured at up to three separate points
provided that at least one measurement is greater than 1.5 cm.
Pleural thicknesses should be measured at the same position,
at the same level, and by the same observer at reassessment.
The modified RECIST criteria have been used in the major
trials of chemotherapy of MPM since their development,
including the phase III randomized trial.
Concomitant with advances in imaging assessment,
there has been a realization that certain individuals with
MPM do poorly with therapy, and the search for prognostic
factors that can aid in stratifying such groups has matured.
The Cancer and Leukemia Group B9 has reported that the key
prognostic factors in MPM include performance status, age,
hemoglobin, white blood cell count, chest pain, and weight
loss, and that these may be useful in predicting outcomes for
chemotherapy-treated patients. As performance status, age,
and white blood cell count increase, survival decreases.
Prospective validation of these prognostic groupings and, in
particular, the worst prognostic CALGB cohorts has been
reported.10
THE INFLUENCE OF PEMETREXED
The standard therapy for MPM began to change in 1999
after a key publication from a phase I study showing that the
combination of pemetrexed plus cisplatin had clinical activity
in patients with various solid tumors, including confirmed
partial responses in five of the 11 patients with MPM.11
Pemetrexed is a novel multi-targeted anitfolate that inhibits
glycinamide ribonucleotide formyl transferase and leads to
purine depletion and also inhibits dihydrofolate reductase
(similar to methotrexate) and thymidylate synthase, causing
pyrimidine depletion.12 The combination of purine and py-
rimidine depletion by a single drug is unique among antineo-
plastic agents. The promising phase I clinical data of pem-
etrexed and cisplatin led to the design of a second phase I
study in which carboplatin was combined with pemetrexed in
patients with MPM. This combination regimen resulted in an
overall response rate of 32%, and 70% of the patients noted
an improvement in symptoms.13 Single-agent pemetrexed
was associated with the best survival time (10.7 months)
reported to that date and with a moderate response rate of
14%.14 While these trials were being conducted, it became
clear that drug-related death was associated with severe
gastrointestinal toxicity and severe neutropenia. Investigation
of the phenomenon revealed that an increased homocysteine
level at baseline, along with an increased methylmalonic acid
level, was highly correlated with severe toxicity, suggesting
that they could be relatively folic acid- and/or vitamin B12-
deficient and, thus, also at increased risk of severe toxicity.15
Dietary supplementation with low-dose folic acid (350 to
1000 g) and vitamin B12 (1000 g) intramuscular injec-
tions was shown to markedly improve the tolerability of
pemetrexed while maintaining clinical activity.
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THE PHASE III TRIAL
Based on the encouraging results of phase I trials with
pemetrexed and cisplatin among patients with MPM, a large,
randomized, single-blind phase III study was conducted to
compare the combination of pemetrexed with cisplatin versus
cisplatin alone in patients with MPM.2 The trial randomized
456 eligible patients to pemetrexed 500 mg/m2 IV bolus over
10 minutes plus cisplatin 75 mg/m2 administered every 3
weeks (n  226) or to single-agent cisplatin 75 mg/m2 plus
saline (to preserve blinding) administered every 3 weeks (n
222). A statistically significant longer median survival time
was observed in all patients receiving the combination ther-
apy versus those receiving cisplatin alone (12.1 versus 9.3
months) (hazard ratio [HR]  0.77; P  0.020). One-year
survival rates were also higher in the pemetrexed/cisplatin
group (50.3 versus 38.0%). Median time to progressive dis-
ease was significantly longer for patients in the pemetrexed/
cisplatin arm compared with those in the cisplatin-only arm
(5.7 versus 3.9 months) (HR  0.68, P  0.001). Tumor
response rates (as measured by an average 30% reduction in
the thickness of the pleural rind measured at up to nine points
on the computed tomographic scan) were 41.3% in the
combination arm versus 16.7% in the cisplatin-alone arm
(Fisher’s exact P  0.001). Time to disease progression,
pulmonary function, and quality of life also improved in a
statistically significant manner among pemetrexed/cisplatin-
treated patients.
Serious adverse events were more common with pem-
etrexed/cisplatin than with cisplatin alone (22.5 versus 7.2%);
however, supplementation with folic acid and vitamin B12
resulted in consistent declines in toxicity. In fact, toxicity
analysis revealed that pemetrexed plus cisplatin treatment
with folic acid and vitamin B12 supplementation provided a
superior risk-benefit ratio for patients with MPM without
changes in efficacy. Median survival times for patients who
received supplementation at any time throughout the median
of six cycles of treatment were 13.2 months for patients
treated with pemetrexed/cisplatin and 9.4 months for patients
treated with cisplatin alone (HR 0.71, log-rank P 0.022).
This phase III trial has led to a number of other
follow-up trials of the Alimta cisplatin combination. The
most notable of these trials is a multicenter phase II trial of
induction Alimta and cisplatin followed by extrapleural pneu-
monectomy and postoperative hemithorax radiotherapy. This
trial should be completed in late 2005.
OTHER RECENT PHASE III CHEMOTHERAPY
TRIALS FOR MPM
A phase III trial with raltitrexed, another thymidine
synthase inhibitor, was conducted in combination with cis-
platin and compared with cisplatin alone in patients with
malignant pleural mesothelioma.6 Two hundred fifty patients
were randomized, and among the 213 patients with measur-
able disease, the response rate was 13.6% for cisplatin alone
versus 23.6% for the combination (P  0.056. No difference
in quality of life was observed. Median overall and 1-year
survival favored the combination and were 8.8 months (95%
CI, 7.8–10.8) versus 11.4 months (95% CI, 10.1–15) and
40% versus 46%, respectively (P  0.048).
NEW AGENTS FOR THERAPY OF
MESOTHELIOMA
Ranpirnase is an antineoplastic ribonuclease that has
antitumor activity in mesothelioma.16 In a multicenter trial of
ranpirnase among 105 patients, four of the 81 patients with
evaluable disease had a PR, two had a minor response, and 35
had stabilization of previously progressive disease. For the
entire group, the median survival duration was 6 months, and
the 1- and 2-year survival rates were 34% and 22%, respec-
tively.17 This actually compares favorably to the CALGB
data for the 1- and 2-year survival rates in “good risk” groups
1 to 4 (27% and 12%, respectively). Ranpirnase is presently
being tested in a phase III trial in MPM comparing doxoru-
bicin plus ranpirnase versus doxorubicin alone, and the study
accrual goal is 240 patients.
The rationale for inhibition of angiogenic mechanisms
in MPM is quite strong because vascular endothelial growth
factor, vascular endothelial growth factor C, and their recep-
tors are overexpressed in MPM tissue, cell lines, and pleural
effusions, as well as in some nonmalignant mesothelial spec-
imens and effusions.18 At least three angiogenesis inhibitors,
SU5416 (a tyrosine kinase activity of the vascular endothelial
growth factor receptor flk-1), bevacizumab (Avastin, Genen-
tech, South San Francisco, CA), and thalidomide, have been
or are in clinical trials for the treatment of MPM. SU5416 has
been abandoned for the treatment of MPM. Bevacizumab, a
recombinant human anti-monoclonal antibody that blocks the
binding of vascular endothelial growth factor to its receptors,
is being evaluated in a double-blind, placebo-controlled,
randomized phase II trial.19 This trial includes patients with
both pleural and peritoneal mesothelioma and compares cis-
platin/gemcitabine with or without bevacizumab chemother-
apy and should be presented at the ASCO conference in 2006.
Other targeted agents, including epidermal growth fac-
tor receptor pathway inhibitors (erlotonib), platelet-derived
growth factor receptor pathway (gleevec), and proteasome/
ubiquitin pathway (bortezomib), are presently in trials or
preparing to be tested for the treatment of MPM.
CONCLUSION
There are new agents with improved efficacy for cyto-
toxic therapy for malignant mesothelioma. Combinations of
these agents are associated now with very tolerable toxicity
profiles. Future studies either combining cytotoxics with
targeted agents or using targeted agents alone after chemo-
therapy may further enhance progression-free and overall
survival in these patients.
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